Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series

Exacerbation of psoriasis induced by Nivolumab in a patient with stage IIIc gastric adenocarcinoma: A case report and literature review

“…Some patients needed oral steroids or acitretin (or both of them), and phototherapy could help the symptom. When it comes to patients with psoriatic arthritis, oral methotrexate and prednisolone or apremilast seem to be effective [ [20] , [23] , [24] , [25] , [26] , [43] ]. Apremilast seems to provide a promising choice for those whose psoriasis is refractory as 5 patients got improved after being treated with apremilast [ [34] , [41] , [43] ].…”

“…When it comes to patients with psoriatic arthritis, oral methotrexate and prednisolone or apremilast seem to be effective [ [20] , [23] , [24] , [25] , [26] , [43] ]. Apremilast seems to provide a promising choice for those whose psoriasis is refractory as 5 patients got improved after being treated with apremilast [ [34] , [41] , [43] ]. Risankizumab-rzaa also helped a patient to get improved [ 42 ].…”

“…Secondly, typical treatment of primary psoriasis is effective in this secondary situation, such as topical treatment with steroids or Vitamin D3 analogues in combination with oral prednisolone or acitretin are effective for most patients; phototherapy seems to be safe and effective for psoriasis inversa; methotrexate is needed for psoriatic arthritis [ 23 ]. While given the immunosuppressive effect may be adverse in treating tumor cells, cyclosporine seems to be inappropriate [ 23 , 43 ].…”

Severe de novo pustular psoriasiform immune‐related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma

“…However, in a cohort of 115 patients with psoriasiform irAE, Nikolaou et al 17 reported that 70% of patients had no history of psoriasis. Reports of de novo psoriasis exist, and those associated specifically with nivolumab (20 patients) are summarized in Table 1 20‐37 …”

“…Reports of de novo psoriasis exist, and those associated specifically with nivolumab (20 patients) are summarized in Table 1. [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] The presence or absence of spongiosis and eosinophils in de novo psoriasiform irAE has not been thoroughly reported. None of the cases in our review (Table 1) reported pustular psoriasis with an eosinophilic infiltrate.…”